Dublin, Oct. 19, 2017 -- The "Global Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024" report has been added to Research and Markets' offering.
Global injectable drug delivery is projected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024.
Scope of the Report
- The global injectable drug delivery market is segmented into 2 types, namely injectable drug delivery device and injectable drug delivery formulation.
- Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices.
- The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation.
- On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others.
- The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others.
- Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others.
- On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern.
- On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system.
- On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others.
Becton Dickinson and company is going to dominate the injectable drug delivery market following with Pfizer and Baxter International, Inc.
Market Overview
Drivers
- Rising Cases of Chronic Diseases
- Rising Demand of Self-Injection Devices
- Growth of Biologics Market
- Technological Advancements and Innovations in Drug Delivery Market
Restraints
- Needlestick Injuries and Infections
- High Cost of Development
- Strict Regulatory Framework
Opportunity
- Increasing Demand for Generic and Biosimilar Drugs
- Increasing Demand for Contraceptive Injectables
- Increasing Demand for Self-Administration of Drugs
Challenges
- Alternative Route of Drug Administration
- Product Recall
- Stability of Products
- Sterility of Injections
Key Topics Covered:
1. Introduction
2. Market Segmentation
3. Market Overview
4. Executive Summary
5. Premium Insights
6. Global Injectable Drug Delivery Market, Regulatory
7. Global Injectable Drug Delivery Market, by Type
8. Global Injectable Drug Delivery Market, by Application
9. Global Injectable Drug Delivery Market, by Usage Pattern
10. Global Injectable Drug Delivery Market, by Mode of Administration
11. Global Injectable Drug Delivery Market, by End User
12. Global Injectable Drug Delivery Market, by Distribution Channel
13. Global Injectable Drug Delivery Market, by Geography
14. Global Injectable Drug Delivery Market, Company Share
15. Company Profiles
- Alkermes Plc.
- Baxter International, Inc.
- Becton Dickinson
- Bespak, Antares Pharma
- Elcam Medical
- Eli Lilly and Company
- Gerresheimer AG
- Haselmeier
- Mylan N.V.
- Novo Nordisk
- Owen Mumford Ltd
- Pfizer
- Sandoz
- Sanofi
- Schott AG
- Terumo Corporation
- Teva Pharmaceuticals Industries Ltd.
- West Pharmaceutical Services, Inc
- Ypsomed Holding AG.
For more information about this report visit https://www.researchandmarkets.com/research/mghfqf/global_injectable
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infusions and Injectables


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 



